OVERVIEW

Complementary Insulin Combinations to Optimize Glycemic Control in T2D is organized by CMEducation Resources, LLC. This CME Conference has been approved for a maximum of 2.50 AMA PRA Category 1 Credits.

Release date: July 14, 2017
Expiration date: July 14, 2019

Course Overview :
In this web-based program, physicians and optometrists will learn how recent developments have helped to advance the management of Type 2 diabetes

Conference Objectives are :
Upon completion of this activity, participants will be able to:
• Identify patients who, because of postprandial hyperglycemia, are not optimizing overall HA1c target goal attainment; and who, therefore, may be appropriate candidates for therapy with specific agents, including GLP-1 agonists, in combination with basal insulin, to optimize their glycemic management
• Apply titration strategies for the dose(s) of both basal insulin and a GLP-1 agonist, when used in combination formulations, to achieve optimal HA1c control, weight loss, reduction in risk of hypoglycemia, and postprandial glucose control
• Describe the mechanisms, metabolic issues, and physiological rationale for combining anti-hyperglycemic agents—such as basal insulin, that preferentially targets fasting hyperglycemia, in conjunction with agents such as GLP-1 agonists that preferentially target postprandial hyperglycemia—in order to optimize glycemic management and HA1c targets in patients with T2D
• Identify T2D patients in whom the possible advantages of incretin system-targeted therapy with GLP-1 agonists—including better PPG control, weight loss, and HA1c reductions— may make them guideline-appropriate candidates for combination regimens
• Individualize multimodal, pharmacologic management in patients with T2D, and improve patient outcomes by deploying combination regimens that act through multiple, complementary mechanisms—including new basal insulin and incretin system-targeted combination-based interventions—to achieve ADA/EASD target goals

Additional details will be posted as soon as they are available.